BTIG analyst Ryan Zimmerman maintained a Buy rating on OrthoPediatrics Corp (NASDAQ: KIDS) yesterday and set a price target of $32. The company’s shares closed yesterday at $26.50.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 28.6% and a 68.4% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, SeaSpine Holdings, and Globus Medical.
Currently, the analyst consensus on OrthoPediatrics Corp is a Moderate Buy with an average price target of $31.
See today’s analyst top recommended stocks >>
Based on OrthoPediatrics Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $5 million. In comparison, last year the company had a GAAP net loss of $1.27 million.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KIDS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OrthoPediatrics Corp. is a medical device company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. Its products includes PediLoc®, PediPlates®, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc® Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, RESPONSE Spine, Bandloc and Pediguard. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.
